Society for Pediatric Dermatology

Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Catch up on coverage from the second day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Caulfield discusses his SPD 2024 lecture, "The Misinformation Crisis: How Did We Get Here and What Can We Do?"

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the first day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

In this episode, Albert Yan, MD, FAAP, FAAD, discusses his SPD 2024 session revolving around the helpful (or hindering?) role of artificial intelligence and chatbots in dermatology.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

The conference aimed at providing pediatric dermatology clinicians with the latest in the specialty begins tomorrow in Toronto, Ontario.

Ahead of the SPD's Annual Meeting in Toronto, share with us: What do you hope to learn?

Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.

Leading atopic dermatitis experts delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.

Researchers applied EB-101, a new cell therapy, to patients with recessive dystrophic epidermolysis bullosa with positive results.

Jemima Mellerio, MD, said a correct diagnosis often requires a lot of testing, questioning, and observation.

As a parent of a child with a vascular anomaly, Kumar has experienced all the emotions of having a child who is born with a skin condition.

Pediatricians are often the first to diagnose and manage pediatric atopic dermatitis, and Larry Eichenfield, MD, led a team to develop a tool to help them.

As a radiologist with Radiology Associates of Albuquerque, Jessica Williams, MD, offered pearls on imaging for young patients.

Remembering that skin conditions are not just physical, but also have a significant emotional impact, is critical to treating the whole patient.